0001209191-13-045762.txt : 20130926
0001209191-13-045762.hdr.sgml : 20130926
20130926161609
ACCESSION NUMBER: 0001209191-13-045762
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130924
FILED AS OF DATE: 20130926
DATE AS OF CHANGE: 20130926
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 131116991
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2013-09-24
0
0001280600
ACCELERON PHARMA INC
XLRN
0000816284
CELGENE CORP /DE/
86 MORRIS AVENUE
SUMMIT
NJ
07901
0
0
1
0
Common Stock
2013-09-24
4
C
0
457875
A
457875
D
Common Stock
2013-09-24
4
J
0
57899
A
515774
D
Common Stock
2013-09-24
4
C
0
1990446
A
2506220
D
Common Stock
2013-09-24
4
P
0
666667
15.00
A
3172887
D
Series C-1 Convertible Preferred Stock
2013-09-24
4
C
0
457875
0.00
D
Common Stock
457875
0
D
Series E Convertible Preferred Stock
2013-09-24
4
J
0
36496
0.00
D
Common Stock
57899
0
D
Series F Convertible Preferred Stock
2013-09-24
4
C
0
1990446
0.00
D
Common Stock
1990446
0
D
Upon closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date.
Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted at a ratio of 1-for-1.58645 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date.
Upon closing of the Issuer's initial public offering, each share of Series F Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date.
Chairman of the Board of Directors, Chief Executive Officer and President
/s/Robert J Hugin_______________________
Robert J Hugin, Attorney-in-Fact
2013-09-26